CELL INTELLIGENCE · 肿瘤细胞治疗研究

Cancer remains a leading global health challenge, necessitating continuous advancements in diagnostics and therapeutics to enhance patient outcomes. According to the recent data of the American Cancer Society, an estimated 20 million new cancer cases and 9.7 million cancer deaths occurred globally in 2022, with cases projected to reach 35 million by 2050. Early and accurate diagnosis is critical for effective treatment, and the traditional methods often lack sensitivity and specificity. Advanced analytical techniques, comprising molecular and genomic diagnostics, next-generation sequencing (NGS), and artificial intelligence (AI)-driven imaging, have significantly enhanced early detection and real-time tumor monitoring. In therapeutics, precision oncology has emerged as a transformative approach, integrating immunotherapy, gene editing (CRISPR), matrix-assisted laser desorption/ionization (MALDI), CAR-T cell therapy, and nanotechnology-based delivery for targeted treatment. Dual-purpose tools like NGS, predictive modeling, and molecular profiling bridge both domains, enhancing predictive accuracy via multimodal data fusion as a paradigm-shifting analytical platform revolutionizing traditional approaches. Despite advancements, resistance and accessibility challenges entail continued innovation. These advancements, driven by the convergence of biotechnology, data science, and molecular medicine, substantiate diagnostic accuracy and therapeutic precision. This review critically examines current analytical innovations, including molecular, imaging modalities, biosensors, and therapy-guiding analytics, highlighting their integration within precision oncology frameworks.